STANDARD_NAME	VALK_AML_CLUSTER_5
SYSTEMATIC_NAME	M14437
COLLECTION	C2:CGP
MSIGDB_URL	https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/VALK_AML_CLUSTER_5
NAMESPACE	AFFY_HG_U133
DESCRIPTION_BRIEF	Top 40 genes from cluster 5 of acute myeloid leukemia (AML) expression profile; 96% of the samples are FAB M4 or M5 subtype.
DESCRIPTION_FULL	BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
PMID	15084694
GEOID	
AUTHORS	Valk PJ,Verhaak RG,Beijen MA,Erpelinck CA,Barjesteh van Waalwijk van Doorn-Khosrovani S,Boer JM,Beverloo HB,Moorhouse MJ,van der Spek PJ,Löwenberg B,Delwel R
CONTRIBUTOR	Jessica Robertson
CONTRIBUTOR_ORG	MSigDB Team
EXACT_SOURCE	Supplementary Table E1
FILTERED_BY_SIMILARITY	
EXTERNAL_NAMES_FOR_SIMILAR_TERMS	
EXTERNAL_DETAILS_URL	
SOURCE_MEMBERS	200866_s_at,201642_at,202895_s_at,203767_s_at,203768_s_at,203769_s_at,204254_s_at,204392_at,204487_s_at,204619_s_at,204858_s_at,205099_s_at,205685_at,205686_s_at,206278_at,206710_s_at,206934_at,207104_x_at,207224_s_at,207872_s_at,208594_x_at,210146_x_at,210660_at,211135_x_at,211732_x_at,211776_s_at,212334_at,212681_at,213624_at,214590_s_at,217992_s_at,218559_s_at,219593_at,219788_at,219872_at,220066_at,220832_at,221578_at,222218_s_at,50221_at
GENE_SYMBOLS	PSAP,IFNGR2,SIRPAP1,STS,STS,STS,VDR,CAMK1,KCNQ1,VCAN,TYMP,CCR1,CD86,CD86,PTAFR,EPB41L3,SIRPB1,LILRB1,SIGLEC7,LILRA1,LILRB3,LILRB2,LILRA1,LILRB3,HNMT,EPB41L3,GNS,EPB41L3,SMPDL3A,UBE2D1,EFHD2,MAFB,SLC15A3,PILRA,GASK1B,NOD2,TLR8,RASSF4,PILRA,TFEB
FOUNDER_NAMES